Visterra to Present New Preclinical Results on VIS649, its Antibody for the Treatment of IgA Nephropathy, at the American Society of Nephrology Kidney Week Conference - VIS649 Reduced Serum IgA, with Favorable Safety Pro - Kidney failure - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2017-10-30 18:54:27		Visterra to Present New Preclinical Results on VIS649, its Antibody for the Treatment of IgA Nephropathy, at the American Society of Nephrology Kidney Week Conference - VIS649 Reduced Serum IgA, with Favorable Safety Pro Add to Reading List Source URL: www.visterrainc.com Download Document from Source Website File Size: 119,00 KB Share Document on Facebook